Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations with respect to its current and future financial, commercial and operating performance, business plans or prospects, including its expected revenue and profitability. The Com ...

Core Viewpoint - Alkermes reported quarterly earnings of $1.04 per share, exceeding the Zacks Consensus Estimate of $0.81 per share, and showing significant growth from $0.48 per share a year ago, indicating a strong performance in the recent quarter [1] Group 1: Earnings Performance - The earnings surprise for the recent quarter was 28.40%, compared to a previous quarter where the company reported earnings of $0.73 per share against an expectation of $0.78, resulting in a surprise of -6.41% [1][2] - Over the last four quarters, Alkermes has surpassed consensus EPS estimates only once [2] Group 2: Revenue Performance - Alkermes generated revenues of $429.99 million for the quarter ended December 2024, which surpassed the Zacks Consensus Estimate by 13.56% and increased from $377.48 million year-over-year [2] - The company has exceeded consensus revenue estimates two times in the last four quarters [2] Group 3: Stock Performance and Outlook - Alkermes shares have appreciated approximately 11.1% since the beginning of the year, outperforming the S&P 500's gain of 3.2% [3] - The future stock price movement will largely depend on management's commentary during the earnings call and the earnings outlook [3][4] Group 4: Earnings Estimates and Industry Outlook - The current consensus EPS estimate for the upcoming quarter is $0.39 on revenues of $325.75 million, and for the current fiscal year, it is $1.87 on revenues of $1.39 billion [7] - The Medical - Biomedical and Genetics industry, to which Alkermes belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable industry outlook [8]

Corporate Presentation at J.P. Morgan Healthcare Conference - Alkermes plc will present its corporate presentation at the J.P. Morgan Healthcare Conference on January 15, 2025, including expectations for cash and investments for the year ended December 31, 2024 [5] - The corporate presentation is furnished as Exhibit 99.1 and incorporated by reference in Item 7.01 [6] - Alkermes plc's corporate presentation is listed as Exhibit 99.1 in the Exhibit Index [9] Form 8-K Filing Information - The information in the Form 8-K, including Items 2.02 and 7.01, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 [7]

Financial Performance - Total revenues for 2024 were reported at $1.56 billion, with proprietary product net sales increasing approximately 18% year-over-year [1][3] - GAAP net income from continuing operations was $372 million, translating to diluted GAAP earnings per share of $2.20 for 2024 [1][3] - The company generated over $1 billion in revenue from its proprietary commercial product portfolio and delivered EBITDA from continuing operations of approximately $452 million [2][3] Product Performance - Proprietary net sales for the fourth quarter of 2024 were $307.7 million, compared to $242.0 million in the same quarter of 2023, marking a significant increase [3][12] - Key products included VIVITROL® with revenues of $134.1 million (up 31% year-over-year), ARISTADA® with $96.6 million (up 16%), and LYBALVI® with $77.0 million (up 37%) [3][12] Operational Developments - The company completed the sale of its manufacturing business in Ireland and ended 2024 debt-free with approximately $825 million in cash and investments [2][13] - Ongoing Phase 2 studies for ALKS 2680 in narcolepsy are expected to yield data in the second half of 2025, with plans to initiate additional studies in idiopathic hypersomnia [2][1] Financial Expectations for 2025 - The company anticipates total revenues between $1.34 billion and $1.43 billion for 2025, with specific net sales expectations for VIVITROL, ARISTADA, and LYBALVI [15] - Projected GAAP net income for 2025 is estimated to be between $175 million and $205 million, with EBITDA expected to range from $215 million to $245 million [15][34]

Core Viewpoint - Alkermes plc will host a conference call and webcast on February 12, 2025, to discuss its fourth quarter and year-end 2024 financial results, along with financial expectations for 2025 and company updates [1]. Company Overview - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience, with a portfolio addressing alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [3]. - The company has a pipeline of clinical and preclinical candidates targeting neurological disorders, including narcolepsy and idiopathic hypersomnia [3]. - Alkermes is headquartered in Ireland, with additional offices and facilities in Massachusetts and Ohio [3].

Group 1 - Alkermes plc will participate in two upcoming investor conferences: the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024, and the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024 [1] - The live webcasts of the conferences will be accessible under the Investors tab on Alkermes' website and will be archived for 14 days [1] Group 2 - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience [2] - The company has a portfolio of proprietary commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [2] - Alkermes is headquartered in Ireland, with additional offices in Massachusetts and a manufacturing facility in Ohio [2]

Group 1 - Alkermes plc will participate in two upcoming investor conferences: Stifel Healthcare Conference on November 18, 2024, at 8:35 a.m. ET and Jefferies London Healthcare Conference on November 19, 2024, at 8:00 a.m. ET [1] - Live webcasts of the conferences will be available under the Investors tab on Alkermes' website and will be archived for 14 days [1] Group 2 - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience [2] - The company has a portfolio of proprietary commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [2] - Alkermes has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia [2] - The company is headquartered in Ireland, with additional offices in Massachusetts and a manufacturing facility in Ohio [2]

Alkermes plc (ALKS) reported adjusted earnings from continuing operations of 73 cents per share for thirdquarter 2024, which missed the Zacks Consensus Estimate of 78 cents. The company had reported adjusted earnings of 87 cents per share in the year-ago quarter. ALKS' total revenues of $378.1 million declined 0.7% from the year-ago quarter's level owing to lower manufacturing and royalty revenues. The top line, also, missed the Zacks Consensus Estimate of $386 million. Shares of Alkermes were down 3.6% on ...

Financial Data and Key Metrics Changes - Alkermes reported total revenues of $378.1 million for Q3 2024, reflecting an 18% year-over-year growth driven by proprietary products [10][11] - The company achieved GAAP net income from continuing operations of $92.8 million and non-GAAP net income of $121.4 million for the quarter [14] - Cash and total investments at the end of Q3 stood at $927.8 million, with approximately $116 million used for share repurchases [14] Business Line Data and Key Metrics Changes - VIVITROL net sales reached $113.7 million, a 14% increase year-over-year, with expectations for full-year sales between $410 million and $430 million [5][11] - ARISTADA product family generated net sales of $84.7 million, with expectations for full-year sales towards the lower end of the $340 million to $360 million range due to market softness [6][11] - LYBALVI net sales were $74.7 million, showing a 37% year-over-year growth, with full-year expectations between $275 million and $295 million [7][11] Market Data and Key Metrics Changes - The overall schizophrenia long-acting antipsychotic market is experiencing softness, which is expected to persist through the end of the year [6] - The company noted that approximately 55% to 57% of new patient starts for LYBALVI are coming from bipolar 1 disorder, indicating strong growth in that segment [40] Company Strategy and Development Direction - Alkermes plans to focus on driving profitability while increasing investments in growth opportunities, particularly in proprietary products and R&D initiatives [15][16] - The company aims to manage the business to deliver significant profitability and cash flow in 2025, with expectations of over $200 million in EBITDA [16][56] - Alkermes is committed to advancing the ALKS 2680 clinical program and exploring additional orexin receptor agonist candidates for future development [19][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of proprietary products and the ability to navigate competitive dynamics in the antipsychotic space [8][10] - The company is monitoring the impact of GLP-1 drugs on VIVITROL but currently does not foresee significant competition affecting its sales [25] - Management highlighted the importance of maintaining a robust cash-generating business while investing in R&D and commercial strategies [15][56] Other Important Information - Alkermes has transitioned to a financial profile driven by proprietary products and an efficient operating structure [10] - The company is actively managing its share repurchase program, with $200 million remaining from the $400 million authorization [14][61] Q&A Session Summary Question: Impact of GLP-1 drugs on VIVITROL - Management is monitoring the market but does not currently see GLP-1 drugs impacting VIVITROL sales [25] Question: Need for abuse potential studies for orexin candidates - Management confirmed that they will look at preclinical and clinical abuse potential studies for CNS active compounds [27] Question: Clarification on EBITDA guidance for 2025 - Management explained that the decrease in EBITDA guidance is primarily due to the transition away from INVEGA SUSTENNA revenue and increased R&D spending [30][31] Question: Market dynamics for LYBALVI and competition - Management noted strong growth in new patient starts for LYBALVI, particularly in bipolar 1 disorder, and does not foresee significant impact from new competitors [40][41] Question: Business development and pipeline expansion - Management expressed interest in adding non-covariate assets to the pipeline but emphasized the need for thorough due diligence [47] Question: Efficacy concerns for orexin candidates - Management indicated that the efficacy waning seen in other studies does not apply to ALKS 2680, which has shown effectiveness across a range of doses [50] Question: Future EBITDA trends and profitability - Management stated that they expect to maintain profitability while investing in growth, with plans to manage the business for sustained profitability [56][70]

Alkermes (ALKS) reported $378.14 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 0.7%. EPS of $0.73 for the same period compares to $0.64 a year ago.The reported revenue represents a surprise of -2.06% over the Zacks Consensus Estimate of $386.09 million. With the consensus EPS estimate being $0.78, the EPS surprise was -6.41%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determin ...